A 2-period, Fixed-sequence, Open-label Study to Evaluate the Effect of Multiple Oral Doses of Diltiazem on the Single-dose Pharmacokinetics of MK-6916 in Healthy Participants
Latest Information Update: 21 Mar 2025
At a glance
- Drugs MK 6916 (Primary) ; Diltiazem
- Indications Unspecified
- Focus Pharmacokinetics
- Acronyms MK-6916-005
- Sponsors Merck Sharp & Dohme
- 17 Mar 2025 Status changed from not yet recruiting to recruiting.
- 18 Feb 2025 Planned End Date changed from 23 Apr 2025 to 27 May 2025.
- 18 Feb 2025 Planned primary completion date changed from 23 Apr 2025 to 27 May 2025.